Navigation Links
Up to 20 million euros for Munich Catalysis research cooperation
Date:11/29/2010

ture of chemical products based on alternative resources, such as natural gas, coal or renewable (biogenic) raw materials.

This strategic cooperation will play an important role in the TUMs overall strategy of bundling university research activities in the field of chemical catalysis. The research alliance is to be integrated into a new central institute for catalysis research set up by the TUM (Catalysis Research Center, CRC). As from 2012, it will be housed in the new CRC building currently under construction on the TUM campus in Garching. The CRC bundles the TUMs broad scientific spectrum in the field of catalysis research with focus on industry-related research.

"The overriding goal envisaged by Munich Catalysis is to develop key catalytic technologies on a sustainable basis which in view of the limited fossil resources and a continuing rise in the global consumption of energy and base chemicals make the greatest demands on research alliances between university and industry," says the TUMs President, Professor Wolfgang A. Herrmann. "As an entrepreneurial university, our research activities pursue the path of innovation to the stage of technical realization. In the field of catalysis, we have selected Sd-Chemie since this partner has a globally successful catalyst business."

Upon signing the agreement, Dr. Gnter von Au, Managing Board Chairman of Sd-Chemie AG, said: "Chemical catalysis is a key technology and will be making a major contribution to the development of economically and ecologically sustainable ways of manufacturing fuel and chemicals in times when resources are in increasingly short supply. This pioneering venture is a means of bundling our numerous scientific cooperation projects with the TUM in the field of catalysis research based on a future-oriented and highly efficient industry-on-campus concept. In this way, we will continue to strengthen the TUMs academic base in this high-potential sector, while also achieving
'/>"/>

Contact: Dr. Andreas Battenberg
battenberg@zv.tum.de
49-892-891-0510
Technische Universitaet Muenchen
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Researcher explores the evolution of largest mammals over the past 100 million years
2. $1.6 million to take forward breakthrough research in heart disease
3. NIH awards $10 million to advance microneedle patch for flu vaccination
4. Aeras awarded €11.7 million ($16 million) grant from Dutch government
5. $2.7 million research award to aid nursery, floriculture industry
6. New statistical model moves human evolution back 3 million years
7. Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC
8. USAID awards $5 million to CONRAD
9. $12 million grant to probe root causes of heart failure
10. MegaMatcher Accelerator 3.0 for Rapid Biometric Identification Matches Up to 200 Million Irises or 100 Million Fingerprints Per Second
11. NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Up to 20 million euros for Munich Catalysis research cooperation
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Brain cells in a mouse model of Alzheimer's,disease ... the disorder's characteristic brain plaques are removed.,Researchers at ... mice with an antibody for a key component ... areas of the brain where,antibodies cleared plaques, many ...
... with aiding efforts to study addicted,smokers, a new ... brain that have,been implicated in nicotine addiction ... such as Alzheimer’s,disease and schizophrenia.,Developed by UC Irvine ... ?Nifrolidine ?is a selective binding agent,that identifies specific ...
... cells have been contaminated with a non-human molecule ... to research by investigators at the University of ... Salk Institute in La Jolla,California.,In a study published ... the researchers found that human embryonic stem cells,including ...
Cached Biology News:Mouse brain cells rapidly recover after Alzheimer's plaques are cleared 2Mouse brain cells rapidly recover after Alzheimer's plaques are cleared 3Drug That 'Tags' Decision-making Areas Of The Brain May Aid 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 3Current human embryonic stem cell lines contaminated UCSD/Salk team finds 4
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... the "Genotyping Market by Technology, Application & by ... their offering. The global genotyping market is ... Billion in 2015, at a CAGR of 22.3% during ... Market growth will be attributed to the availability of ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 “Stem Cell Therapy ... more mainstream, and it is used often as an adjunct ... general practitioners are not yet aware or comfortable enough with ... therapy is most often reserved for the last resort cases ... pet can barely lift a paw to get around. It ...
(Date:6/2/2015)... , June 2, 2015  RXi ... biotechnology company focused on discovering and developing ... dermatology and ophthalmology, today announced that Dr. ... will present at the 23 rd ... world congress will include in-depth presentations by ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Through rare ... technology, Yancy Corporation is enabling World Scientists ... material and biological sample, displaying the full nature (position, ... between atoms. , Jeff Porter, Co-Founder of the Yancy ... just that – rare. They come once in a ...
Breaking Biology Technology:Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2
... ... , ... , , ... ...
... ... ... , ... , , , ...
... ... ... , ... ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Reports Full Year Results 2009 2Amsterdam Molecular Therapeutics Reports Full Year Results 2009 3Amsterdam Molecular Therapeutics Reports Full Year Results 2009 4Amsterdam Molecular Therapeutics Reports Full Year Results 2009 5Amsterdam Molecular Therapeutics Reports Full Year Results 2009 6Amsterdam Molecular Therapeutics Reports Full Year Results 2009 7Amsterdam Molecular Therapeutics Reports Full Year Results 2009 8Amsterdam Molecular Therapeutics Reports Full Year Results 2009 9Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 2Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 4Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 5Predicted Second Wave of Biotech Growth and Development Begins 2Predicted Second Wave of Biotech Growth and Development Begins 3Predicted Second Wave of Biotech Growth and Development Begins 4Predicted Second Wave of Biotech Growth and Development Begins 5Predicted Second Wave of Biotech Growth and Development Begins 6Predicted Second Wave of Biotech Growth and Development Begins 7Predicted Second Wave of Biotech Growth and Development Begins 8Predicted Second Wave of Biotech Growth and Development Begins 9Predicted Second Wave of Biotech Growth and Development Begins 10Predicted Second Wave of Biotech Growth and Development Begins 11
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Affinity Purified Anti-Human NP-1...
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
HES-1 [Hairy 1], Available Summer 2003...
Biology Products: